Redeye provides an initial take on the Q2 2025 report from Scandinavian ChemoTech. Net sales were SEK3.85m (1.68), up an exceptional 128% y/y. EBIT reached SEK-0.7m (-3.76), showing that the company is close to reaching breakeven. Despite a c200% increase in the share price from the April lows, we maintain our positive view of the company, building on the rapidly growing recurring revenue, high gross margins, and solid cost control. We expect to slightly increase our fair value range on the back of the report.
LÄS MER
